INSY - INSYS Therapeutics, Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
65,799,000.00
-2.20 (-0.00%)
As of 6:07PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.29
Open0.27
Bid0.00 x 800
Ask0.00 x 900
Day's Range0.25 - 0.38
52 Week Range0.14 - 11.65
Volume11,293,950
Avg. Volume8,812,876
Market Cap4,995.46T
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateAug 6, 2019 - Aug 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.60
Trade prices are not sourced from all markets
  • GlobeNewswire

    FDA Accepts New Drug Application for INSYS Therapeutics’ Naloxone Nasal Spray for the Emergency Treatment of Known or Suspected Opioid Overdose

    INSYS Therapeutics, Inc. (OTCMKTS:INSYQ), announced today that its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational, proprietary naloxone nasal spray for the emergency treatment of known or suspected opioid overdose in both adult and pediatric patients has been accepted for filing.  INSYS’ naloxone nasal spray is a single unit dose spray device that delivers 8mg naloxone dose. “The FDA’s acceptance of the NDA for INSYS’ proprietary formulation of a naloxone nasal spray is an important milestone in battling the U.S. opioid epidemic,” said Dr. Venkat Goskonda, chief scientific officer at INSYS Therapeutics. INSYS Therapeutics is a specialty pharmaceutical company using proprietary technology and capabilities to develop and commercialize innovative pharmaceutical products intended to address unmet medical needs and the clinical shortcomings of existing commercial products.

  • Opinion: Medical Marijuana Is a Terrible Investment
    Motley Fool

    Opinion: Medical Marijuana Is a Terrible Investment

    Medical marijuana drug developers are often smothered in hype and rarely deliver any reward.

  • Insys Therapeutics Bankruptcy: INSY Stock Soars on Latest News
    InvestorPlace

    Insys Therapeutics Bankruptcy: INSY Stock Soars on Latest News

    Insys Therapeutics bankruptcy news for Wednesday has INSY stock heading higher.Source: Insys TherapeuticsInsys Therapeutics (NASDAQ:INSY) notes that it now has approval from the U.S. Bankruptcy Court for the District of Delaware for its First Day motions. It received this approval on Tuesday, but only just announced the news today.This approval will allow the company to move forward with its Insys Therapeutics bankruptcy plans. This marks a move in the right direction for the company as it looks to use the bankruptcy protection to cover its legacy legal liabilities.InvestorPlace - Stock Market News, Stock Advice & Trading TipsWith the First Day motions approval, Insys Therapeutics will be able to continue operations throughout the bankruptcy process. This includes it continuing to pay employees for their work. It will also let the company keep paying its vendors."This is an important step forward in our court-supervised process, which is intended to fairly and transparently address the Company's legacy legal liabilities," Andrew Long, CEO of Insys Therapeutics, said in a statement. "I would like to thank our team for their continued hard work and dedication as we move forward with our asset sale process." * 7 Stocks to Buy for the Coming Recession The Insys Therapeutics bankruptcy won't just have the company selling off some of its assets to cover its legal costs. Instead, it will be selling "substantially all" of its assets during the process.INSY stock was up 189% as of noon Wednesday, but is down 96% since the start of the year. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Stocks to Buy for the Coming Recession * 10 Smart Dividend Stocks for the Rest of the Year * 5 Tech Stocks That Are Far Too Risky Right Now As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Insys Therapeutics Bankruptcy: INSY Stock Soars on Latest News appeared first on InvestorPlace.

  • Zynerba Up on Second Patent for Cannabidiol Candidate in 2019
    Zacks

    Zynerba Up on Second Patent for Cannabidiol Candidate in 2019

    Zynerba (ZYNE) gets a new U.S. patent covering methods of treating autism spectrum disorder with cannabidiol, a key compound of its lead pipeline candidate, Zygel.

  • Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash
    Zacks

    Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash

    Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

  • MarketWatch

    Insys Therapeutics' stock jumps after bankruptcy court approves 'First Day' motions

    Shares of Insys Therapeutics Inc. shot up 83% in premarket trade Wednesday, after the bankrupt opioid maker said it received interim court approvals for its "First Day" motions related to bankruptcy filing on Monday. The rally comes after the stock closed at a record low of 14 cents on Tuesday, a far cry from its split-adjusted record high of $641.95 on Sept. 28, 2000. The company said it was granted approval to continue paying its employees and vendors, and to continue its cash management system. "This is an important step forward in our court-supervised process, which is intended to fairly and transparently address the Company's legacy legal liabilities," said Chief Executive Andrew Long.

  • GlobeNewswire

    INSYS Therapeutics, Inc. Receives Court Approval of “First Day” Motions

    INSYS Therapeutics, Inc. (INSY) (“INSYS” or the “Company”), a specialty pharmaceutical development and distribution company, announced that on June 11, 2019 INSYS received interim approvals from the U.S. Bankruptcy Court for the District of Delaware for its First Day motions related to the Chapter 11 petitions filed on June 10, 2019. Andrew G. Long, Chief Executive Officer of INSYS Therapeutics, Inc., said, “This is an important step forward in our court-supervised process, which is intended to fairly and transparently address the Company’s legacy legal liabilities. The Court granted INSYS interim approval to continue its existing cash management system to collect and disburse cash generated by the business.

  • Insys Down on Bankruptcy News Amid Increasing Legal Expenses
    Zacks

    Insys Down on Bankruptcy News Amid Increasing Legal Expenses

    Insys (INSY) crashes as it files for bankruptcy protection amid rising legal settlement dues.

  • Investors are pinning hopes on this asset again — but beware, says Saxo Bank
    MarketWatch

    Investors are pinning hopes on this asset again — but beware, says Saxo Bank

    Our call of the day, from Saxo Bank’s head of commodity strategy Ole Hansen, cautions investors against getting too excited over this haven asset again too soon.

  • Chandler opioid maker files for bankruptcy protection
    American City Business Journals

    Chandler opioid maker files for bankruptcy protection

    Costs related to recent federal settlements and other lawsuits have forced the Valley drugmaker to file for bankruptcy protection.

  • Insys Therapeutics Bankruptcy: INSY Stock Plunges on the News
    InvestorPlace

    Insys Therapeutics Bankruptcy: INSY Stock Plunges on the News

    The Insys Therapeutics bankruptcy news coming out on Monday has INSY stock tanking hard.Source: Insys TherapeuticsInsys Therapeutics (NASDAQ:INSY) says that it has filed for Chapter 11 bankruptcy protection. The company will be using this time to sell off assets of its business in an effort to cover legacy legal liabilities.Companies filing for bankruptcy to reorganize their business is one thing, but the Insys Therapeutics bankruptcy is particularly bad. The company isn't just planning to sell off some of its assets. Instead, it notes that it will be selling "substantially all" of its assets.InvestorPlace - Stock Market News, Stock Advice & Trading TipsWhile the Insys Therapeutics bankruptcy is taking place, the company says that it plans to continue normal operations. This includes paying wages to employees, continuing benefits and making payments to vendors. * 7 Stocks to Buy As They Hit 52-Week Lows Andrew G. Long, CEO of the company, has this to say about the Insys Therapeutics bankruptcy news."After conducting a thorough review of available strategic alternatives, we determined that a court-supervised sale process is the best course of action to maximize the value of our assets and address our legacy legal challenges in a fair and transparent manner. INSYS has compelling assets and a highly talented team. We believe this process will provide us with a forum to negotiate an equitable resolution with our creditors and represents the best opportunity for our people and our business."INSY stock was down 52% as of Monday afternoon and is down 69% year-to-date. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Stocks to Buy As They Hit 52-Week Lows * 4 Antitrust Tech Stocks to Keep an Eye On * 5 Gold and Silver Stocks Touching Intraday Highs As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Insys Therapeutics Bankruptcy: INSY Stock Plunges on the News appeared first on InvestorPlace.

  • TheStreet.com

    Insys Therapeutics Sinks After Filing for Bankruptcy

    was down 36% in trading Monday after the company announced it will be filing for Chapter 11 bankruptcy protection due to the financial burden from litigation tied to its role in the opioid crisis in the United States. It said it would continue to operate its business "in the ordinary course" while it sells off its assets through bankruptcy court. Just last week, Insys agreed to pay $225 million to settle federal charges over its opioid sales.

  • MarketWatch

    Insys files for bankruptcy, stock plunges toward record low

    Shares of Insys Therapeutics Inc. plunged 68% toward a record low in premarket trade Monday, after the specialty pharmaceutical company said it filed for bankruptcy. Insys said it plans to continue operating its business while it pursues the sale of substantially all of its assets. "After conducting a thorough review of available strategic alternatives, we determined that a court-supervised sale process is the best course of action to maximize the value of our assets and address our legacy legal challenges in a fair and transparent manner," said Chief Executive Andrew Long. As of Dec. 31, Insys had 226 full-time employees. The company reported a 2018 net loss of $124.3 million, or $1.68 a share, on revenue of $82.1 million, after a loss of $227.0 million, or $3.12 a share, on revenue of $140.7 million in 2017. The stock has lost 81% over the past 12 months through Friday, while the SPDR S&P Pharmaceuticals ETF has declined 13% and the S&P 500 has gained 3.4%.

  • Opioid manufacturer Insys files for bankruptcy after kickback probe
    Reuters

    Opioid manufacturer Insys files for bankruptcy after kickback probe

    The Chapter 11 bankruptcy filing marked a first for a drugmaker accused in lawsuits of helping fuel the deadly U.S. opioid endemic and came just days after Insys struck a $225 million settlement with the Justice Department. The department is now Insys' largest unsecured creditor due to Wednesday's accord, which resulted in a subsidiary pleading guilty to fraud charges and the company entering into a deferred prosecution agreement. The bankruptcy filing came after a federal jury in Boston in May found Insys founder John Kapoor and four other former executives guilty of engaging in a racketeering conspiracy centered on its fentanyl spray, Subsys.

  • Reuters

    UPDATE 4-Opioid manufacturer Insys files for bankruptcy after kickback probe

    Drugmaker Insys Therapeutics Inc filed for bankruptcy protection on Monday amid mounting expenses driven by a U.S. Justice Department probe into claims it paid doctors bribes to prescribe a powerful opioid medication. The Chapter 11 bankruptcy filing marked a first for a drugmaker accused in lawsuits of helping fuel the deadly U.S. opioid endemic and came just days after Insys struck a $225 million settlement with the Justice Department. The department is now Insys' largest unsecured creditor due to Wednesday's accord, which resulted in a subsidiary pleading guilty to fraud charges and the company entering into a deferred prosecution agreement.

  • GlobeNewswire

    INSYS Therapeutics Initiates Court-Supervised Process to Facilitate Asset Sales and Address Legacy Liabilities

    INSYS Therapeutics, Inc. (INSY) (“INSYS” or the “Company”), a specialty pharmaceutical development and distribution company, announced today that INSYS has filed voluntary cases (the “Chapter 11 Cases”) under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court in the District of Delaware (the “Court”) to facilitate the sale of substantially all of the Company’s assets and address the Company’s legacy legal liabilities. INSYS intends to continue operating its business in the ordinary course while it pursues these transactions through the court-supervised sale process.

  • 3 Marijuana Stocks I Wouldn't Touch With a 10-Foot Pole Right Now
    Motley Fool

    3 Marijuana Stocks I Wouldn't Touch With a 10-Foot Pole Right Now

    Some marijuana stocks are worth a serious look. These aren't.

  • Opioid manufacturer agrees to pay $225 million to settle corruption case
    MarketWatch

    Opioid manufacturer agrees to pay $225 million to settle corruption case

    Opioid maker Insys Therapeutics Inc., faced allegations that it paid kickbacks and used other illegal marketing tactics to sell the highly-addictive fentanyl spray.

  • Chandler opioid maker agrees to $225M settlement, admits to bribing docs
    American City Business Journals

    Chandler opioid maker agrees to $225M settlement, admits to bribing docs

    The multimillion-dollar settlement comes a month after several former executives with the company were found guilty on racketeering charges.

  • 3 Marijuana Stocks Hitting All-Time Lows
    Motley Fool

    3 Marijuana Stocks Hitting All-Time Lows

    Though many cannabis investors are seeing green, these pot stocks have gone up in smoke.

  • Pfizer's (PFE) Epilepsy Drug Lyrica Fails in Phase III Study
    Zacks

    Pfizer's (PFE) Epilepsy Drug Lyrica Fails in Phase III Study

    Pfizer (PFE) announces failure of a phase III study evaluating Lyrica in patients with primary generalized tonic-clonic seizures, a form of epilepsy.

  • Top Trending: Insys files for bankruptcy, Hudson's Bay offers to go private and more
    Yahoo Finance Video

    Top Trending: Insys files for bankruptcy, Hudson's Bay offers to go private and more

    Yahoo Finance's Adam Shapiro fills you in on the top trending news stories that you need to know.